Onfekafusp alfa
- Generic Name
- Onfekafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1957239-88-1
- Unique Ingredient Identifier
- 6HXC0O6JMV
- Background
Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).
- Associated Conditions
- -
- Associated Therapies
- -
Sun Pharma shares slip 5% as pharma major is stopped from launching Leqselvi drug
Sun Pharma shares fell 4.9% on BSE due to a US court injunction delaying Leqselvi launch. The company plans to appeal. Despite this, Sun Pharma reported a 28% rise in Q2 FY25 net profit to ₹3,040 crore, with revenue up 9% to ₹13,291.39 crore. The company also expanded its dermatology pipeline with Fibromun.
Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy
Sun Pharma and Philogen have agreed on a global exclusive commercialization, license, and supply agreement for Fibromun (L19TNF), an anti-cancer immunotherapy. Philogen will handle trials, approval, and manufacturing, while Sun Pharma will lead global commercialization. Post-commercialization profits will be split 55:45 in favor of Sun Pharma. Fibromun has shown promise in treating soft-tissue sarcomas and glioblastoma, transforming 'cold' tumors into 'hot' for enhanced immune recognition.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath